BENEFIT–RISK ASSESSMENT OF UPADACITINIB TREATMENT IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS

Remo Panaccione  ¹     Irina Blumenstein  ²     Peter Irving  ³     Ramona Vladea  ⁴     Dapo Ilo     Wen Zhou     Gweneth Levy     Xuan Yao     Iris Dotan  ^5    
1 University of Calgary, Calgary, Canada
² JW Goethe University Hospital, Frankfurt, Germany
³ Guy's and St Thomas' Hospital, London, United Kingdom
⁴ AbbVie Inc., North Chicago, United States
⁵ Tel Aviv University, Tel Aviv, Israel

Session
Clinical trials in IBD (Posters)

Conference
UEG Week 2022

Citation
United European Gastroenterology Journal 2022; 10 (Supplement 8)